INT112717

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 2003
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 21
Total Number 21
Disease Relevance 11.07
Pain Relevance 0.99

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (VEGFA) growth (VEGFA) extracellular region (VEGFA)
proteinaceous extracellular matrix (VEGFA) cytoplasm (VEGFA)
Anatomy Link Frequency
endothelial cells 2
cardiac myocytes 2
fibroblast 2
VEGFA (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 35 100.00 Very High Very High Very High
antagonist 21 98.32 Very High Very High Very High
cytokine 37 95.60 Very High Very High Very High
rheumatoid arthritis 58 87.72 High High
dysesthesia 2 80.56 Quite High
Paresthesia 2 80.04 Quite High
peripheral neuropathy 3 78.76 Quite High
Arthritis 8 75.00 Quite High
cva 78 71.48 Quite High
chemokine 3 62.68 Quite High
Disease Link Frequency Relevance Heat
INFLAMMATION 38 100.00 Very High Very High Very High
Diabetic Retinopathy 22 99.08 Very High Very High Very High
Cancer 428 98.88 Very High Very High Very High
Necrosis 10 98.64 Very High Very High Very High
Vomiting 24 97.66 Very High Very High Very High
Leukemia 55 96.80 Very High Very High Very High
Corneal Neovascularization 24 96.52 Very High Very High Very High
Infection 6 95.96 Very High Very High Very High
Diabetes Mellitus 25 95.24 Very High Very High Very High
Pre-eclampsia 33 94.04 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Counter to prevailing wisdom, simulated increase in production of sVEGFR1 did not lead to significant reduction in intramuscular VEGF-VEGFR2 complex formation.
Negative_regulation (reduction) of VEGF-VEGFR2 Binding (formation) of
1) Confidence 0.56 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
Bevacizumab is a humanized murine antihuman VEGF monoclonal IgG1 antibody that blocks the binding of human VEGF to its receptors, thereby also disrupting autocrine and paracrine survival mechanisms mediated by VEGFR-1 and VEGFR-2 [55].
Negative_regulation (blocks) of VEGF Binding (binding) of
2) Confidence 0.42 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2875768 Disease Relevance 0.37 Pain Relevance 0
Bevacizumab is a humanized murine anti-human VEGF monoclonal IgG1 antibody that blocks the binding of human VEGF to its receptors, thereby disrupting also autocrine and paracrine survival mechanisms mediated by VEGFR-1 and VEGFR-2 [67].
Negative_regulation (blocks) of VEGF Binding (binding) of
3) Confidence 0.42 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 0.56 Pain Relevance 0
This was sufficient to elevate the fractional occupancy of total sVEGFR1 (e.g., +9%) despite decreasing free sVEGFR1; yet not enough to prevent overall reductions in bound fraction of total VEGF (e.g., -14%) because of the greater increase in free VEGF.
Negative_regulation (reductions) of VEGF Binding (bound) of
4) Confidence 0.41 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0.06 Pain Relevance 0
This was sufficient to elevate the fractional occupancy of total sVEGFR1 (e.g., +9%) despite decreasing free sVEGFR1; yet not enough to prevent overall reductions in bound fraction of total VEGF (e.g., -14%) because of the greater increase in free VEGF.
Negative_regulation (prevent) of VEGF Binding (bound) of
5) Confidence 0.41 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0.06 Pain Relevance 0
Blocking the interaction between VEGF and Flk-1/KDR can abolish VEGF induced proliferation.
Negative_regulation (Blocking) of VEGF Binding (interaction) of
6) Confidence 0.41 Published 2007 Journal BMC Nephrol Section Body Doc Link PMC1852096 Disease Relevance 1.03 Pain Relevance 0
Free sVEGFR1 concentrations, however, changed in opposite directions: lowered with increasing VEGF-VEGFR1 affinity but rose with increasing VEGF-VEGFR2 affinity.
Negative_regulation (lowered) of VEGF-VEGFR1 Binding (affinity) of
7) Confidence 0.41 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
Bevacizumab is a recombinant monoclonal antibody and it inhibits the binding of VEGF-A to its receptor by binding to VEGF-A [28].
Negative_regulation (inhibits) of VEGF Binding (binding) of
8) Confidence 0.37 Published 2010 Journal Korean Journal of Ophthalmology : KJO Section Body Doc Link PMC2916105 Disease Relevance 0.52 Pain Relevance 0
Bevacizumab leads to rapid clearance of circulating VEGF, but is not known to affect VEGF bound to receptor, as the epitope on VEGF recognized by bevacizumab is in the VEGF-R binding region.
Negative_regulation (epitope) of VEGF Binding (recognized) of
9) Confidence 0.32 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004565 Disease Relevance 0.99 Pain Relevance 0
These drugs use decoy soluble receptors to bind VEGF and thereby prevent VEGF binding to its receptors.
Negative_regulation (prevent) of VEGF Binding (binding) of
10) Confidence 0.30 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895781 Disease Relevance 1.28 Pain Relevance 0.29
Currently two major concepts are studied in the clinical setting: blocking VEGF from binding to its extracellular receptors with VEGF antagonists (antibodies, VEGF-Trap) or inhibiting VEGF signaling with tyrosine kinase inhibitors (TKIs) [62].
Negative_regulation (blocking) of VEGF Binding (binding) of associated with antagonist
11) Confidence 0.29 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2902148 Disease Relevance 0.49 Pain Relevance 0.08
Agents that directly inhibit the actions of VEGF and its receptors show considerable promise (Caldwell et al 2005).
Negative_regulation (inhibit) of VEGF Neg (inhibit) Binding (actions) of
12) Confidence 0.28 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2704517 Disease Relevance 1.06 Pain Relevance 0.10
This may in part be due to a reduced postoperative inflammation-mediated angiogenic stimulus directed by the proangiogenic factor VEGF and its neutralizing receptor VEGFR1.
Negative_regulation (reduced) of VEGF Binding (directed) of associated with inflammation
13) Confidence 0.24 Published 2005 Journal Inflamm. Res. Section Abstract Doc Link 16307219 Disease Relevance 0.10 Pain Relevance 0.05
The binding of bevacizumab to VEGF prevents VEGF binding to its receptors on the surface of endothelial cells.
Negative_regulation (prevents) of VEGF Binding (binding) of in endothelial cells
14) Confidence 0.22 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895781 Disease Relevance 0.67 Pain Relevance 0.06
However, binding of VEGF to cell transmembrane receptors is reduced by a soluble circulating form of Flt-1 (sFlt-1), which is generated by alternative splicing.
Negative_regulation (reduced) of VEGF Binding (binding) of
15) Confidence 0.21 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2739214 Disease Relevance 0.41 Pain Relevance 0
In this review, the authors integrate current knowledge of VEGF signaling and information on VEGF antagonists gleaned experimentally and place emphasis on the use of synthetic anti-VEGF hexapeptide to prevent VEGF interacting with its receptor.


1.

Negative_regulation (prevent) of VEGF Binding (interacting) of associated with antagonist
16) Confidence 0.21 Published 2008 Journal Mediators of Inflammation Section Abstract Doc Link PMC2638142 Disease Relevance 1.04 Pain Relevance 0.34
The nature of this antibody is known to be related to bevacizumab therapy [19, 33] and this antibody has been shown to inhibit the binding of human and murine VEGF to VEGF-receptors in vitro and has also been shown to be effective against rat VEGF [33].
Negative_regulation (inhibit) of VEGF Binding (binding) of
17) Confidence 0.20 Published 2010 Journal Acta Histochemica et Cytochemica Section Body Doc Link PMC2875861 Disease Relevance 0.81 Pain Relevance 0
VEGFR 2 binding activates a number of signaling pathways (29) and the antibody inhibits them all by blocking binding of VEGF to its receptor.
Negative_regulation (blocking) of VEGF Binding (binding) of
18) Confidence 0.16 Published 2010 Journal Apmis Section Body Doc Link PMC2806050 Disease Relevance 0.06 Pain Relevance 0
Known for its antiemetic and teratogenic properties, the biologic modifier thalidomide is also thought to be antiangiogenic both directly by inhibiting basic fibroblast growth factor and VEGF and indirectly by blocking tumor necrosis factor ?
Negative_regulation (inhibiting) of VEGF Binding (factor) of in fibroblast associated with necrosis, cancer and vomiting
19) Confidence 0.12 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2962304 Disease Relevance 0.88 Pain Relevance 0.07
Podoplanin suppresses endogenous VEGF-C but not other lymphangiogenesis-related growth factor gene expressions in vivo and in vitro
Negative_regulation (suppresses) of VEGF Binding (endogenous) of
20) Confidence 0.08 Published 2010 Journal Mol Cancer Section Body Doc Link PMC2987985 Disease Relevance 0.68 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox